Publication Name	World Journal of Gastroenterology
Manuscript ID	73047
Country	India

Received	2021-11-07 14:22
Peer-Review Started	2021-11-07 14:23
To Make the First Decision
Return for Revision	2021-12-12 05:39
Revised	2021-12-25 07:07
Second Decision	2022-06-24 03:15
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2022-06-24 22:09
Articles in Press	2022-06-24 22:09
Publication Fee Transferred
Edit the Manuscript by Language Editor	2022-06-19 21:50
Typeset the Manuscript	2022-07-07 09:19
Publish the Manuscript Online	2022-07-18 09:47

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Letter to the Editor
Article Title	Hepatitis B core-related antigen: Are we near a treatment endpoint?
Manuscript Source	Unsolicited Manuscript
All Author List	Tarana Gupta
ORCID	Author(s) ORCID Number Tarana Gupta http://orcid.org/0000-0003-3453-2040
Funding Agency and Grant Number
Corresponding Author	Tarana Gupta, Doctor, MBBS, MD, Professor, Medicine, Pandit Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences, House No. 1065 A Sector 1, Rohtak 124001, Haryana, India. taranagupta@gmail.com
Key Words	Hepatitis B core-related antigen; Chronic hepatitis B; Covalently closed circular DNA; Hepatitis B e antigen seroconversion; Hepatitis B virus DNA; Pregenomic RNA
Core Tip	This study highlights the predictive role of hepatitis B core-related antigen (HBcrAg) levels at baseline, and after 24 and 48 wk of antiviral therapy for hepatitis B e antigen seroconversion in chronic hepatitis B patients. The issues related to poor sensitivity of assays and detectable levels in hepatitis B surface antigen-negative patients are major concerns. Future research on the utility of HBcrAg in hepatitis B virus (HBV) flare after nucleotide cessation, occult HBV reactivation, and risk of developing hepatocellular carcinoma is also needed.
Publish Date	2022-07-18 09:47
Citation	Gupta T. Hepatitis B core-related antigen: Are we near a treatment endpoint? World J Gastroenterol 2022; 28(27): 3532-3534
URL	https://www.wjgnet.com/1007-9327/full/v28/i27/3532.htm
DOI	https://dx.doi.org/10.3748/wjg.v28.i27.3532

Full Article (PDF)	WJG-28-3532.pdf
Full Article (Word)	WJG-28-3532.docx
Manuscript File	73047_Auto_Edited-LM .docx
Answering Reviewers	73047-Answering reviewers.pdf
Audio Core Tip	73047-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	73047-Conflict-of-interest statement.pdf
Copyright License Agreement	73047-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate	73047-Language certificate.pdf
Peer-review Report	73047-Peer-review(s).pdf
Scientific Misconduct Check	73047-Bing-Wang JJ-2.png
Scientific Editor Work List	73047-Scientific editor work list.pdf